XML 37 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information (Notes)
 9 Months Ended
Sep. 30, 2018
Segment Reporting Information [Line Items]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
20. Segment Information

In connection with acquiring 100% of the equity interests of LENSAR in May 2017, the Company added a third reportable segment, “Medical Devices” and renamed the previous product sales segment “Pharmaceutical”.

Information regarding the Company’s segments for the three and nine months ended September 30, 2018 and 2017 is as follows:
Revenues by segment
 
Three Months Ended
 
Nine Months Ended
 
 
September 30,
 
September 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
$
17,772

 
$
15,104

 
$
61,993

 
$
43,897

Medical devices
 
6,615

 
4,963

 
17,479

 
7,580

Income generating assets
 
43,511

 
42,682

 
73,519

 
200,547

Total revenues
 
$
67,898

 
$
62,749

 
$
152,991

 
$
252,024


Income (loss) by segment
 
Three Months Ended
 
Nine Months Ended
 
 
September 30,
 
September 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
$
4,132

 
$
1,082

 
$
(108,916
)
 
$
(3,560
)
Medical Devices
 
(934
)
 
(5,598
)
 
(3,425
)
 
(6,774
)
Income Generating Assets
 
22,358

 
25,248

 
27,203

 
98,746

Total net income (loss)
 
$
25,556

 
$
20,732

 
$
(85,138
)
 
$
88,412


Information regarding the Company’s segments as of September 30, 2018 and December 31, 2017 is as follows:
Long-lived assets by segment
 
 
 
 
(in thousands)
 
September 30,
2018
 
December 31,
2017
 
 
 
 
 
Pharmaceutical
 
$
3,965

 
$
822

Medical Devices
 
4,739

 
6,263

Income Generating Assets
 
134

 
137

Total long-lived assets
 
$
8,838

 
$
7,222



The operations for the Company’s Pharmaceutical and Medical Devices segments are primarily located in Ireland and the United States, respectively.